InTheMoney
I’m Adam (InTheMoney). I trade stocks and options, teach both, and share market commentary on YouTube. Content is educational only — not financial advice.
Past bets that played out
Content is largely opinion-driven and promotional. Highlighted themes include bearish sentiments on individual names (e.g., SoFi / SOFI), macro/market bubble commentary, and critical takes on growth/consumer tech names. Most standout posts are rhetorical or entertainment-focused, with few concrete, repeatable trade setups or verifiable catalysts.
A promotional, rant-style post that frames Duolingo as overhyped/overvalued (“billion-dollar delusion”) and explicitly suggests the author wants to short the stock, but provides no concrete new data, catalyst, or verifiable claims beyond sentiment.
Promotional/entertainment-style post framing the market as a bubble and discussing being heavily leveraged, with references to Buffett-style sentiment and “The Big Short.” The provided excerpt contains no concrete positions, catalysts, or specific tickers/sectors to evaluate.
The source is a clickbait-style commentary arguing inflation is rising due to tariffs (costs passed through to consumers with a lag), not primarily due to monetary policy. Implication: higher/stickier inflation increases the risk of higher-for-longer rates, multiple compression for equities, and pressure on rate-sensitive growth stocks.
What this channel is watching now
Frequently discussed tickers: QQQ (most-mentioned), TLT, TQQQ, and single-mention interest in AMD, CSV, DNA, ITM, and MUST. Coverage mixes broad Nasdaq exposure and select single-name commentary; conviction levels vary and many posts lack detailed, actionable analysis.
Latest videos and market context
Recent videos range from clickbait-style market commentary (SpaceX IPO speculation, Duolingo critique) to personal updates and promotional content for paid services/Discord tools. Several recent posts are promotional or limited to high-level opinions without concrete trade timing, signals, or catalysts.
SpaceX IPO: T-1 to Rugpull
The provided body contains promotional links and general investing disclaimers, with no substantive analysis or concrete, tradable information about a SpaceX IPO beyond the sensational title (“T-1 to Rugpull”). As a result, actionable signals, catalysts, timing, and tickers are largely absent.
The Space X IPO is NOT Chill - A Channel Update
The provided source contains only a title and repeats it in the body, with no additional details, data, timing, or claims. It mentions SpaceX and an IPO but provides no actionable information for trading or thesis construction.
Why SoFi Ain’t It
The source is a largely incoherent rant centered on a bearish view of SoFi (SOFI), referencing short interest/shorting, and mentions buying puts and briefly buying the Vanguard Growth ETF (VUG). It lacks concrete catalysts, numbers, timing, or a clear repeatable setup beyond a general “short/puts” posture on SOFI.
Why SoFi Ain’t It
Why SoFi Ain’t It subscriptions revenue top's going up earnings comes around and um we won't shorts and so they're going to you know find companies to short but if you look at the short interest it's like 15% cost you're buying into a stock where we legitimate and then the the stock moons then everyone drops a stock like it's getting [ __ ] like 10 calls in a row than get spam calls from somebody from a bubbles. SL AI on the banking. What who to short, but we don't know whether it's even looked, but you know, you get a CSV on my PC which literally just the other a power line and scorched my PSU which access to the CSV files of a closed know buying some puts this morning like you can make that yield by buying VG for calls from people trying to give me
Proof-backed call history
Creator has been producing investing and options content for ~12 years. The archive includes a mix of trade-oriented videos, promotional posts for paid services (LEAPS management, Autopilot copy-trading), and personal updates, including health-related posts about an autoimmune encephalitis flare and IVIG treatment.
The source is a largely incoherent rant centered on a bearish view of SoFi (SOFI), referencing short interest/shorting, and mentions buying puts and briefly buying the Vanguard Growth ETF (VUG). It lacks concrete catalysts, numbers, timing, or a clear repeatable setup beyond a general “short/puts” posture on SOFI.
The source is a largely incoherent rant centered on a bearish view of SoFi (SOFI), referencing short interest/shorting, and mentions buying puts and briefly buying the Vanguard Growth ETF (VUG). It lacks concrete catalysts, numbers, timing, or a clear repeatable setup beyond a general “short/puts” posture on SOFI.
Why SoFi Ain’t It subscriptions revenue top's going up earnings comes around and um we won't shorts and so they're going to you know find companies to short but if you look at the short interest it's like 15% cost you're buying into a stock where we legitimate and then the the stock moons then everyone drops a stock like it's getting [ __ ] like 10 calls in a row than get spam calls from somebody from a bubbles. SL AI on the banking. What who to short, but we don't know whether it's even looked,
Why SoFi Ain’t It subscriptions revenue top's going up earnings comes around and um we won't shorts and so they're going to you know find companies to short but if you look at the short interest it's like 15% cost you're buying into a stock where we legitimate and then the the stock moons then everyone drops a stock like it's getting [ __ ] like 10 calls in a row than get spam calls from somebody from a bubbles. SL AI on the banking. What who to short, but we don't know whether it's even looked,
Post is mostly a personal update and promotion for the author's Discord-based AI chatbot that mimics their personality, answers investing questions, and can critique uploaded portfolio screenshots. It briefly mentions asking the bot why AMD moved, but provides no actual AMD-specific analysis. The health portion says the author had an autoimmune encephalitis flare treated with IVIG, a common therapy, but that it was not effective in their acute phase. Overall, this is very low-value for public-ma
Promotional post for a paid service/video about managing LEAPS (long-dated options), with links to try a product and copy portfolios. No specific market news, catalysts, positions, or tickers disclosed.
Promotional post for a paid service/video about managing LEAPS (long-dated options), with links to try a product and copy portfolios. No specific market news, catalysts, positions, or tickers disclosed.
Promotional/disclaimer post advertising an “Autopilot” copy-trading/portfolio mirroring platform and a paid membership/alerts service. Contains affiliate links and general investing-risk disclaimers, but no company-specific news, financial results, macro data, or actionable trading catalyst tied to any publicly traded ticker.
Personal update from the author about being hospitalized for autoimmune encephalitis flare and receiving IVIG; includes a brief market comment noting a “red morning” but only a “tiny dip” in “CuteDQ” and encourages staying calm (implicit dip-buy / hold Nasdaq exposure).
Personal update from the author about being hospitalized for autoimmune encephalitis flare and receiving IVIG; includes a brief market comment noting a “red morning” but only a “tiny dip” in “CuteDQ” and encourages staying calm (implicit dip-buy / hold Nasdaq exposure).
The post is primarily a personal health update: the author is hospitalized for a relapse of autoimmune encephalitis and receiving IVIG, but expects improvement after treatment from their neurologist. The only market-relevant content is a brief reassurance to followers to stay calm during a 'red morning' and a 'tiny dip' in what appears to be QQQ/Nasdaq exposure. No company-specific operational, demand, earnings, or product intelligence is provided.
The source claims Novo Nordisk is suing Hims & Hers and discusses implications for the stock, but the provided body contains only promotional links/disclaimers and no factual details (claims, timing, court, requested remedies). Based on the headline alone, this would most likely relate to Novo defending GLP-1 IP/branding and/or limiting compounded/telehealth distribution, which is typically negative for Hims’ GLP-1-related growth narrative and modestly supportive for branded GLP-1 manufacturers.
About this channel
Adam (handle: inthemoneyadam) presents educational content about investing, trading, and options from a practitioner’s perspective. He emphasizes that all content is educational and not financial advice. The channel blends market commentary, trade ideas, product promotions, and community offerings.
I’m Adam. I invest and trade and options, and teach about both. AKA ya boy. Been at it for 12 years. Nothing here is financial advice. Educational content only.
Most recognized assets
Unlock the full track record
Subscribe on YouTube @inthemoneyadam for market commentary and options education. Content is educational only — do your own research before trading or investing.
21 more thesis calls are available after sign-up.